Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT02052388 is registered in ClinicalTrials.gov with Cellceutix Corporation as lead sponsor.

NCT NCT02052388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Lead sponsor
Cellceutix Corporation
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
October 31, 2014
Enrollment
215 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infection, skin infection